Campbell & CO Investment Adviser LLC Purchases 63,102 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• Campbell & CO Investment Adviser LLC increased its holdings in Halozyme Therapeutics by 162.2% in the first quarter, acquiring an additional 63,102 shares to reach a total of 102,008 shares.
• CEO Helen Torley sold 20,000 shares of the company's stock on August 12th, valuing the transaction at approximately $1.27 million, which decreased her overall holdings by 2.65%.
• Halozyme Therapeutics recently reported earnings of $1.54 per share for the latest quarter, surpassing analysts' expectations and indicating a 40.8% year-over-year revenue growth.

Campbell & CO Investment Adviser LLC grew its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 162.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 102,008 shares of the biopharmaceutical company's stock after purchasing an additional 63,102 shares during the quarter. Halozyme Therapeutics makes up 0.5% of Campbell & CO Investment Adviser LLC's holdings, making the stock its 14th biggest holding. Campbell & CO Investment Adviser LLC owned approximately 0.08% of Halozyme Therapeutics worth $6,509,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Heck Capital Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at about $29,000. SVB Wealth LLC acquired a new stake in shares of Halozyme Therapeutics during the first quarter valued at about $33,000. Bessemer Group Inc. boosted its stake in shares of Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 207 shares in the last quarter. Brooklyn Investment Group boosted its stake in shares of Halozyme Therapeutics by 1,558.1% during the first quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 670 shares in the last quarter. Finally, Park Place Capital Corp boosted its stake in shares of Halozyme Therapeutics by 20.1% during the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock valued at $69,000 after purchasing an additional 182 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on HALO shares. Morgan Stanley lifted their price objective on Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an "overweight" rating in a research note on Monday, August 18th. JMP Securities lifted their price objective on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a research note on Wednesday, August 6th. Benchmark lowered Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. HC Wainwright lifted their price objective on Halozyme Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Wednesday, August 6th. Finally, Leerink Partners lowered Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective on the stock. in a research note on Tuesday, May 13th. Four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of "Hold" and a consensus target price of $67.11.

Insider Activity at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the completion of the sale, the chief executive officer owned 733,719 shares in the company, valued at $46,598,493.69. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold a total of 80,000 shares of company stock worth $4,532,600 in the last ninety days. Insiders own 2.40% of the company's stock.

Halozyme Therapeutics Trading Up 0.0%

HALO traded up $0.03 during trading on Friday, hitting $72.84. The company's stock had a trading volume of 275,341 shares, compared to its average volume of 1,959,960. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $74.07. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. The stock's fifty day moving average price is $60.28 and its 200-day moving average price is $59.16. The firm has a market capitalization of $8.52 billion, a P/E ratio of 16.66, a PEG ratio of 0.42 and a beta of 1.17.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.31. The firm had revenue of $325.72 million for the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company's revenue was up 40.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.